Literature DB >> 25584005

Expanded RAS: refining the patient population.

Chloe E Atreya1, Ryan B Corcoran2, Scott Kopetz3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25584005      PMCID： PMC4334773          DOI： 10.1200/JCO.2014.58.9325

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  24 in total

1.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas.

Authors:  Efsevia Vakiani; Manickam Janakiraman; Ronglai Shen; Rileen Sinha; Zhaoshi Zeng; Jinru Shia; Andrea Cercek; Nancy Kemeny; Michael D'Angelica; Agnes Viale; Adriana Heguy; Philip Paty; Timothy A Chan; Leonard B Saltz; Martin Weiser; David B Solit
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Authors:  Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

3.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Sandra Misale; Rona Yaeger; Sebastijan Hobor; Elisa Scala; Manickam Janakiraman; David Liska; Emanuele Valtorta; Roberta Schiavo; Michela Buscarino; Giulia Siravegna; Katia Bencardino; Andrea Cercek; Chin-Tung Chen; Silvio Veronese; Carlo Zanon; Andrea Sartore-Bianchi; Marcello Gambacorta; Margherita Gallicchio; Efsevia Vakiani; Valentina Boscaro; Enzo Medico; Martin Weiser; Salvatore Siena; Federica Di Nicolantonio; David Solit; Alberto Bardelli
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

4.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors:  Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

5.  Hurdles and complexities of codon 13 KRAS mutations.

Authors:  Maria Pia Morelli; Scott Kopetz
Journal:  J Clin Oncol       Date:  2012-08-27       Impact factor: 44.544

6.  Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

Authors:  Sabine Tejpar; Ilhan Celik; Michael Schlichting; Ute Sartorius; Carsten Bokemeyer; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2012-06-25       Impact factor: 44.544

7.  Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Authors:  Manickam Janakiraman; Efsevia Vakiani; Zhaoshi Zeng; Christine A Pratilas; Barry S Taylor; Dhananjay Chitale; Ensar Halilovic; Manda Wilson; Kety Huberman; Julio Cezar Ricarte Filho; Yogindra Persaud; Douglas A Levine; James A Fagin; Suresh C Jhanwar; John M Mariadason; Alex Lash; Marc Ladanyi; Leonard B Saltz; Adriana Heguy; Philip B Paty; David B Solit
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

8.  Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.

Authors:  Mariella Dono; Carlotta Massucco; Silvana Chiara; Claudia Sonaglio; Marco Mora; Anna Truini; Giannamaria Cerruti; Gabriele Zoppoli; Alberto Ballestrero; Mauro Truini; Manlio Ferrarini; Simona Zupo
Journal:  Mol Med       Date:  2013-02-08       Impact factor: 6.354

9.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

10.  qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles.

Authors:  Sarah Song; Katia Nones; David Miller; Ivon Harliwong; Karin S Kassahn; Mark Pinese; Marina Pajic; Anthony J Gill; Amber L Johns; Matthew Anderson; Oliver Holmes; Conrad Leonard; Darrin Taylor; Scott Wood; Qinying Xu; Felicity Newell; Mark J Cowley; Jianmin Wu; Peter Wilson; Lynn Fink; Andrew V Biankin; Nic Waddell; Sean M Grimmond; John V Pearson
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240
View more
  24 in total

1.  Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.

Authors:  G Passot; Y S Chun; S E Kopetz; M J Overman; C Conrad; T A Aloia; J-N Vauthey
Journal:  Eur J Surg Oncol       Date:  2016-03-05       Impact factor: 4.424

2.  Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort.

Authors:  Michael Levi; Gintang Prayogi; Farid Sastranagara; Edi Sudianto; Grace Widjajahakim; Winiarti Gani; Albert Mahanadi; Jocelyn Agnes; Bela Haifa Khairunisa; Ahmad R Utomo
Journal:  J Gastrointest Cancer       Date:  2018-06

3.  Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

Authors:  Humaid O Al-Shamsi; Jeremy Jones; Yazan Fahmawi; Ibrahim Dahbour; Aziz Tabash; Reham Abdel-Wahab; Ahmed O S Abousamra; Kenna R Shaw; Lianchun Xiao; Manal M Hassan; Benjamin R Kipp; Scott Kopetz; Amr S Soliman; Robert R McWilliams; Robert A Wolff
Journal:  J Gastrointest Oncol       Date:  2016-12

Review 4.  Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen.

Authors:  Nicole E Lopez; Carrie Y Peterson
Journal:  Clin Colon Rectal Surg       Date:  2016-09

5.  Role of Biologics in Colon Cancer: Still Not Clear.

Authors:  Chloe E Atreya; Alan P Venook
Journal:  J Oncol Pract       Date:  2016-12       Impact factor: 3.840

Review 6.  Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases.

Authors:  Guillaume Passot; Olivier Soubrane; Felice Giuliante; Giuseppe Zimmitti; Diane Goéré; Suguru Yamashita; Jean-Nicolas Vauthey
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

Review 7.  Molecular testing to optimize therapeutic decision making in advanced colorectal cancer.

Authors:  Thomas J Semrad; Edward J Kim
Journal:  J Gastrointest Oncol       Date:  2016-04

Review 8.  Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer.

Authors:  Kiran Tripathi; Minal Garg
Journal:  J Cell Commun Signal       Date:  2018-01-12       Impact factor: 5.782

9.  Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.

Authors:  Chloe E Atreya; Claire Greene; Ryan M McWhirter; Nabia S Ikram; I Elaine Allen; Katherine Van Loon; Alan P Venook; Benjamin M Yeh; Spencer C Behr
Journal:  J Natl Compr Canc Netw       Date:  2016-12       Impact factor: 11.908

Review 10.  Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.

Authors:  Nele Boeckx; Marc Peeters; Guy Van Camp; Patrick Pauwels; Ken Op de Beeck; Vanessa Deschoolmeester
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.